Sentri7 vs TheraDoc vs VigiLanz, which clinical surveillance software to buy for antimicrobial stewardship
Three real-time clinical surveillance platforms, all EHR-interfaced, none of them publishing a price. What each vendor actually claims, what the interface work costs you in time, and the case for buying none of them.
10 min read
Sentri7, TheraDoc and VigiLanz are the three clinical surveillance platforms a US hospital pharmacy or infection prevention team will usually be shown when it starts shopping for antimicrobial stewardship software. All three are real-time, alert-driven systems that interface with your electronic health record. None of them publishes a price. The practical difference between them is less about features than about which vendor relationship, which interface build, and which corporate owner you are willing to take on.
This page describes each product only from its own vendor documentation, checked in September 2026. Antimicrobe is not affiliated with Wolters Kluwer, Premier or Inovalon, has no partnership with any of them, and competes with all three in a narrow slice of what they do. Where a claim could not be verified from a public source, it says so rather than guessing.
The short version
Sentri7 is sold by Wolters Kluwer and describes a built-in antibiogram most prominently, alongside NHSN antimicrobial use and resistance reporting and standardized antimicrobial administration ratio benchmarking. TheraDoc is sold by Premier and leads on real-time alerting, custom dashboards and NHSN reporting automation across acute and post-acute settings. VigiLanz is now part of Inovalon, sold inside Inovalon's provider platform as pharmacy and clinical surveillance, and vigilanz.com now presents Inovalon's care management suite rather than a standalone company.
All three are platform purchases, not tools. Each assumes an interface to your EHR, an implementation project, and a multi-year contract negotiated through procurement. If what you actually need is a defensible cumulative antibiogram cut by unit and source, all three are an expensive way to get it, and the last section of this page says so plainly.
What each vendor publicly claims
| Sentri7 | TheraDoc | VigiLanz | |
|---|---|---|---|
| Sold by | Wolters Kluwer | Premier Inc. | Inovalon |
| Category | Clinical and pharmacy surveillance | Clinical surveillance | Pharmacy and clinical surveillance |
| EHR interface | Stated as required | Stated as required | Stated as required |
| Real-time alerting | Yes, rule-driven worklists | Yes, custom alerts and dashboards | Yes, adverse drug event and AMS alerts |
| Antibiogram | Yes, described as real-time and customizable | Not on the product page; a 2021 Premier blog mentions an antibiogram feature | Yes, on-demand and trending antibiogram data |
| NHSN AUR reporting | Yes, plus SAAR benchmarking | Yes, reporting automation | Yes, stated as NHSN certified |
| Post-acute and long-term care | Not stated | Yes, acute and post-acute | Not stated |
| Price published | No | No, demo request only | No |
| Standalone brand site live | Yes | Yes | No, folded into inovalon.com |
Sentri7, from Wolters Kluwer
Sentri7 sits inside Wolters Kluwer Health alongside UpToDate and Medi-Span, which matters more than it sounds: buying it usually means buying into a vendor your pharmacy already has a contract with, and that is often the deciding factor in a procurement committee.
On antimicrobial stewardship specifically, Wolters Kluwer's own product pages describe rule-driven prioritization of patients in a central dashboard, monitoring for bug-drug mismatches and patients on antibiotics without a positive culture, automated NHSN antimicrobial use and resistance submission, standardized antimicrobial administration ratio calculation for benchmarking against national data, and a real-time, customizable antibiogram. The one-click intervention note back into the EHR is the workflow feature stewardship pharmacists tend to mention first. In the 2026 Best in KLAS report, released in February 2026, Sentri7 was ranked first in pharmacy surveillance and Sentri7 Infection Prevention first in infection control and monitoring, according to Wolters Kluwer's announcement.
The antibiogram claim is the one worth probing on a demo. Ask whether it de-duplicates to the first isolate per patient per period, whether it applies a suppression threshold, which breakpoint table version it uses, and whether the exported report prints those rules. A real-time antibiogram that cannot state its own method is a dashboard, not a report you can hand to a committee.
Sentri7 is one of six platforms that sell a mismatch alert. How they compare, and how often such alerts lead to an intervention, is in bug-drug mismatch software compared.
TheraDoc, from Premier
TheraDoc has been in this market a long time and is now sold as Premier's clinical surveillance offering. Premier's page leads on speed of infection response, real-time data interfaced with the EHR, custom alerts and dashboards, NHSN reporting automation, and support for both acute and post-acute settings. That last point is a genuine differentiator: most clinical surveillance vendors do not say anything about post-acute care, and a health system with skilled nursing beds under the same corporate umbrella has a real reason to ask about it.
Premier's clinical surveillance page does not mention antibiograms at all. That is not evidence the product cannot produce one, and older TheraDoc material discusses susceptibility reporting, but it does tell you where the product is being positioned in 2026: infection response and regulatory reporting, not cumulative susceptibility analysis.
Pricing is a demo request. There is no published tier, no per-bed rate, and no trial.
VigiLanz, now inside Inovalon
VigiLanz spent years as the independent clinical surveillance company with a strong reputation among pharmacy directors, including repeated Best in KLAS recognition for pharmacy surveillance. It is now part of Inovalon and is presented as pharmacy surveillance within Inovalon's provider cloud.
The ownership change is a procurement fact worth knowing before a renewal conversation rather than during one. When this page was checked in September 2026, vigilanz.com presented Inovalon's care management suite and the product documentation lived on inovalon.com. Public material describes EHR-integrated medication monitoring, real-time adverse drug event and antimicrobial stewardship alerting, opioid stewardship, on-demand and trending antibiogram data, access to eMAR administration and microbiology search pages for validation, and NHSN-validated antimicrobial use and resistance reporting. Inovalon's 2025 overviews split it into a Starter tier that covers AUR reporting only and a Pro tier with full stewardship, analytics and antibiograms.
If you are evaluating VigiLanz now, the questions that matter are continuity questions. Who owns the roadmap, what happens to your support escalation path, and what the contract says about the product being repackaged inside a larger platform. Those are reasonable things to ask any acquired vendor, and a good one will answer them without flinching.
If you are already on it and weighing the renewal, the VigiLanz alternatives and competitors page walks through the Starter, base and Pro tiers and where the antibiogram sits.
If you already run Sentri7 and are weighing a switch, our Sentri7 alternatives and competitors page covers what to check before you give notice.
Sentri7 vs VigiLanz for precision dosing, and where InsightRx fits
If Bayesian vancomycin dosing is on your requirements list, the three platforms are not equal. Wolters Kluwer offers Bayesian dosing inside Sentri7 Pharmacy through integrations with PrecisePK and DoseMeRx, with patient-specific vancomycin dose recommendations reviewed from the surveillance worklist. Inovalon announced in October 2025 that DoseMeRx is embedded directly in VigiLanz Pharmacy Surveillance. Premier's TheraDoc page does not mention precision dosing.
InsightRx is a different kind of purchase: a standalone model-informed precision dosing company whose Nova product does Bayesian dosing and whose Apollo dashboard analyzes the dosing and pharmacokinetic data it produces. If the choice is InsightRx Apollo versus a surveillance platform, you are really choosing between a dosing specialist that sits beside your EHR and a surveillance platform with dosing added. Neither produces a cumulative antibiogram as its main output, and Antimicrobe does not do dosing at all.
How InsightRx Nova, DoseMeRx and PrecisePK compare on EHR fit, published accuracy and budget is covered in best Bayesian vancomycin dosing software for hospitals.
What none of them publish, and what that costs you
None of the three publishes a price. That is normal for enterprise clinical software and it is also the single largest hidden cost in the evaluation, because it forces every comparison through a sales cycle before you can rank options on value.
The list price is rarely the whole number either. A clinical surveillance contract usually carries an implementation fee, an interface build to your EHR and your laboratory information system, annual maintenance, and an uplift clause. The interface is the part that surprises people: it is generally scheduled in months, it consumes your own IT team as well as the vendor's, and it is what makes a mid-year start date unrealistic. Ask for the total three-year cost, itemized, including every interface, before you compare anything.
Do you need a clinical surveillance platform at all?
This is the question that gets skipped, and for a lot of facilities the honest answer is no. Real-time alerting earns its cost when someone is on shift to act on the alerts. If your stewardship program is one pharmacist with eight hours a week, a stream of real-time bug-drug mismatch alerts becomes a backlog, and the platform becomes an expensive way to feel behind.
Separate the two jobs before you shop. Real-time intervention needs an EHR-interfaced surveillance platform, and only one of these three will do. Retrospective analysis, which covers the annual cumulative antibiogram, the unit-level and source-level cuts, the empiric guideline rewrite and most of what an accreditation surveyor asks to see, needs a susceptibility export and a tool that handles it correctly. That second job does not need an interface, an implementation, or a sales cycle.
If your hospital runs Epic, there is a fourth option on the table: building the stewardship alerts in Epic itself. What the published Epic builds took, and when a platform is still the better buy, is in Epic antimicrobial stewardship module vs third-party tools.
It is also worth being precise about what these platforms are not. The dosing checks, interaction screening and renal adjustment prompts a prescriber wants at the moment of ordering belong to clinical decision support at the point of prescribing, which is a separate product category with separate buyers, and no surveillance platform substitutes for it.
What we do, and where we do not compete
Antimicrobe does the retrospective half only. It takes the susceptibility export your laboratory already produces, de-duplicates to the first isolate per patient, applies a breakpoint set and a suppression threshold, and produces a CLSI M39-shaped cumulative antibiogram cut by source, unit and period, plus a ranked list of empiric options by local percent susceptible. It runs in a browser. The demo parses your CSV client-side and never uploads it.
It does not do real-time alerting, does not connect to an electronic health record, does not compute days of therapy or defined daily doses, and does not submit to NHSN. If those are your requirements, buy one of the three above. If your requirement is a defensible antibiogram and the cuts under it, a platform purchase is the long way round.
The prices are on our pricing page, in full, with every limit. That is not a feature so much as a deliberate contrast with the paragraph above about sales cycles.
What is the difference between clinical surveillance and antimicrobial stewardship software?
Clinical surveillance is the broader category: a platform that watches live clinical data and raises alerts for infection, adverse drug events and medication safety across a hospital. Antimicrobial stewardship software is a use case inside it, focused on antibiotic appropriateness, de-escalation and antibiotic use reporting. All three products here are surveillance platforms sold with a stewardship module rather than stewardship-only tools.
Do you need an EHR interface for antimicrobial stewardship software?
For real-time alerting, yes. Sentri7, TheraDoc and VigiLanz all state that they interface with the electronic health record, because an alert about a patient currently on an antibiotic requires live administration and microbiology data. For retrospective work, no. A cumulative antibiogram is built from a finalized susceptibility export, which is a file, not a feed, and any facility that can run a report from its laboratory information system already has what it needs.
Is TheraDoc still supported?
Yes. TheraDoc is actively marketed by Premier as its clinical surveillance product, with a live product page and a demo request path as of September 2026. The vendor that has changed shape recently is VigiLanz, which now sits inside Inovalon rather than trading under its own domain.
A short evaluation checklist
- Ask for the three-year total, itemized, with every interface and the annual uplift clause in writing
- Ask who builds the EHR and laboratory interfaces, how long it takes, and how many of your own IT hours it consumes
- If an antibiogram is in scope, ask how it de-duplicates, which breakpoint table it applies, and whether the export prints those rules
- Count the hours per week you actually have to work alerts before buying an alerting platform
- For an acquired vendor, ask who owns the roadmap and what the contract says about repackaging
- Separate real-time and retrospective requirements on paper before the first demo, so you can tell which one you are being sold
Related on this site: pharmacy surveillance software, bug-drug mismatch software compared, the free desktop option and where it fits, the long-term care version of this problem, running the program these platforms support, our plans and limits, published, TheraDoc competitors and alternatives at renewal.